Plain-English translation of NCT07575919 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called CD22/CD19 CAR-T cell therapy for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The treatment involves taking some of your own immune cells, engineering them in the laboratory to fight cancer, and then infusing them back into your body. This study will assess whether the medication is safe and effective as a consolidation therapy — meaning additional treatment after your initial chemotherapy — to help prevent the cancer from coming back.
Patients with standard-risk B-ALL who respond well to initial chemotherapy still face a risk of relapse. This trial is exploring whether this medication can be used after chemotherapy to strengthen the body's ability to fight any remaining cancer cells and reduce the chance of the disease returning.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo a procedure called leukapheresis to collect your immune cells, which are then sent to a laboratory to be engineered. You will then receive chemotherapy to prepare your body, followed by infusion of your engineered cells. You will be monitored closely in the hospital and during follow-up visits for at least 2 years to check for safety and how well the treatment is working. During this time, you will have regular blood tests, imaging scans, and clinic visits to track your health and detect any side effects early.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
China